Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02820311 · ClinicalTrials.gov registry record · Phase 1
Thorough QT (TQT) Study of TD-4208 in Healthy Subjects
A Phase 1 study, sponsored by Mylan.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02820311 is a Phase 1 study that has completed, run by Mylan. The registered enrollment target is 48 participants.
The verdict
NCT02820311, a Phase 1 study, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate if TD-4208, an investigational drug being developed to treat people with chronic obstructive pulmonary disease (COPD), has any effect on the electrical activity of the heart.
Interventions
- DRUG Moxifloxacin 400 mg
- DRUG TD-4208 175 mcg
- DRUG TD-4208 700 mcg
- DRUG Placebo for TD-4208
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2016-05 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02820311
The ClinicalTrials.gov registry entry for NCT02820311 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Moxifloxacin 400 mg is the first listed.
NCT02820311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02820311 about?
NCT02820311 is a clinical study titled "Thorough QT (TQT) Study of TD-4208 in Healthy Subjects". The purpose of this study is to evaluate if TD-4208, an investigational drug being developed to treat people with chronic obstructive pulmonary disease (COPD), has any effect on the electrical activity of the heart.
What is the current status of trial NCT02820311?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2016-05. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02820311?
The interventions under investigation include: Moxifloxacin 400 mg (DRUG), TD-4208 175 mcg (DRUG), TD-4208 700 mcg (DRUG), Placebo for TD-4208 (DRUG).
Who is sponsoring clinical trial NCT02820311?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.